SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, Italy.
Italy
SARS-CoV-2
seroprevalence
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
30 06 2022
30 06 2022
Historique:
received:
21
04
2022
revised:
24
06
2022
accepted:
28
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Italy was the second country affected by the SARS-CoV-2 pandemic; the virus spread mainly in Northern Italy with a subsequent diffusion to the center and southern part of the country. In this study, we aimed to assess the prevalence of antibodies against SARS-CoV-2 in the general population of the Siena province in the Tuscany region (Central Italy) during 2020. A total of 2480 serum samples collected from January to December 2020 were tested for IgM and IgG antibodies against SARS-CoV-2 by a commercial ELISA. Positive and borderline samples were further tested for the presence of anti-receptor-binding domain (RBD) IgM and IgG antibodies by an in-house ELISA and by a micro-neutralization assay. Out of the 2480 samples tested by the commercial ELISA, 81 (3.3%) were found to be positive or borderline for IgG and 58 (2.3%) for IgM in a total of 133 samples (5.4%) found to be positive or borderline for at least one antibody class. When the commercial ELISA and in-house ELISA/micro-neutralization assay results were combined, 26 samples (1.0%) were positive for RBD IgG, 11 (0.4%) for RBD IgM, and 23 (0.9%) for a neutralizing antibody. An increase in seroprevalence was observed during the year 2020, especially from the end of summer, consistent with the routine epidemiological surveillance of COVID-19 cases.
Identifiants
pubmed: 35891420
pii: v14071441
doi: 10.3390/v14071441
pmc: PMC9324460
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Immunol Methods. 2021 Feb;489:112937
pubmed: 33253698
J Med Virol. 2021 Mar;93(3):1739-1742
pubmed: 32790086
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Med. 2020 Aug 27;9(9):
pubmed: 32867328
Vaccines (Basel). 2020 Dec 19;8(4):
pubmed: 33352743
Front Public Health. 2021 Jul 16;9:669209
pubmed: 34336767
Future Sci OA. 2021 Jan 12;7(4):FSO673
pubmed: 33815819
Acta Biomed. 2021 Jan 25;92(1):e2021070
pubmed: 33682801
J Clin Lab Anal. 2021 Apr;35(4):e23735
pubmed: 33608968
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Hum Vaccin Immunother. 2022 Nov 30;18(5):2047582
pubmed: 35289714
Tumori. 2021 Oct;107(5):446-451
pubmed: 33176598
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472
pubmed: 34293141
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261716
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
J Infect. 2020 Dec;81(6):e10-e12
pubmed: 32961253
PLoS One. 2021 Jul 2;16(7):e0253977
pubmed: 34214116
Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3342-3349
pubmed: 33928622
J Infect Dis. 2020 Oct 1;222(9):1452-1461
pubmed: 32766833
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Sci Rep. 2020 Nov 18;10(1):20048
pubmed: 33208819
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313